The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms
Abstract
A possible role of vascular and lifestyle-related factors was recently proposed for age-related changes of cognitive function, predementia syndromes, and cognitive decline of degenerative (Alzheimer's disease, AD) or vascular origin (vascular dementia, VaD). At present, cumulative evidence suggests that vascular risk factors may be important in the development of mild cognitive impairment (MCI), dementia, and AD. Among vascular-related factors, metabolic syndrome (MetS) has been associated with the risk of cognitive decline, overall dementia, and VaD, but contrasting findings also existed on the possible role of MetS in AD. If MetS is associated with increased risk of developing cognitive impairment, regardless of mechanism, then early identification and treatment of these individuals at risk might offer new avenues for disease-course modification. Strategies towards early and effective risk factor management could be of value in reducing risk of metabolic and cognitive decline. Future research is needed to confirm the association between MetS and cognitive impairment and to determine the exact mechanism linking them. Such would provide important insights into the causes and interdependencies of predementia and dementia syndromes, and inspire novel strategies for treating and preventing these disorders. At present, vascular risk factor and MetS management could be employed to delay the onset of dementia syndromes or to prevent the progression of predementia syndromes. In the future, trials could be undertaken to determine whether modifications of these risk factors, including inflammation, could lower risk of developing cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Therefore, while one of the most popular theories for the pathogenesis of late-onset AD remains the “amyloid hypothesis” [179], another exciting area is rapidly developing around vascular risk factors as a key part of AD pathology [21].”
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.032 · Cited by 1,888
Comment on the provisional report from the WHO consultation
(1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00059.x · Cited by 1,820 · cited 20×
“Like the EGIR criteria, by the AACE’s definition, once a person develops T2DM, the term insulin resistance syndrome no longer applies.”
Influential15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 1×
“In fact, as seen also for hypertension, elevated BMI in middle age may be associated with higher dementia risk [130–134] (Table 3).”
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 1×
“Diabetes mellitus comprises a strong risk factor for dementia [59] and AD [83,84].”
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Vessby, B., Uusitupa, M., Hermansen, K., Riccardi, G., Rivellese, A. A., Tapsell, L. C., Nälsén, C., Berglund, L., Louheranta, A., Rasmussen, B. M., et al. (2001) · Diabetologia · doi:10.1007/s001250051620 · Cited by 1,119
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102
American College of Endocrinology Position Statement on the Insulin Resistance Syndrome
Einhorn, D. (2003) · Endocrine Practice · doi:10.4158/ep.9.s2.5 · Cited by 1,066
Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies
Cukierman, T., Gerstein, H. C., & Williamson, J. D. (2005) · Diabetologia · doi:10.1007/s00125-005-0023-4 · Cited by 1,049 · cited 1×
“0-fold in individuals with T2DM [99], though a study of cognitive function in the oldest old (age at study entry 85 years) did not find any significant association between T2DM and accelerated cognitive decline [100, 101].”
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025 · cited 2×
“In particular, in the Health Aging and Body Composition Study (Health ABC), cognition was assessed with the Modified Mini-Mental Status Exam (3MS) at baseline, 3, and 5 years with clinically significant cognitive decline defined as Z5-point decline, and baseline MetS was diagnosed using NCEPATP-III criteria [157].”
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829 · cited 1×
“T2DM has been also found consistently to be related to VaD but its relation to AD is less clear [83, 111–118] (Table 2).”
Central obesity and increased risk of dementia more than three decades later
Whitmer, R. A., Gustafson, D. R., Barrett-Connor, E., Haan, M. N., Gunderson, E. P., & Yaffe, K. (2008) · Neurology · doi:10.1212/01.wnl.0000306313.89165.ef · Cited by 803
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
The Effects of Type 1 Diabetes on Cognitive Performance
Brands, A. M. A., Biessels, G. J., de Haan, E. H. F., Kappelle, L. J., & Kessels, R. P. C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.726 · Cited by 738 · cited 1×
“A review of 33 longitudinal studies found that, in patients with type 1 diabetus mellitus, cognitive dysfunction was characterized by a slowing of mental speed and diminished mental flexibility, whereas learning and memory were spared [86,122].”
The Preclinical Phase of Alzheimer Disease: A 22-Year Prospective Study of the Framingham Cohort
Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.808 · Cited by 716 · cited 1×
“Although dementia is primarily a disease of the elderly, epidemiological data suggest that the pathological processes leading to the disease start operating many years before the clinical onset [56,57].”
Inflammatory markers and cognition in well-functioning African-American and white elders
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., & Harris, T. (2003) · Neurology · doi:10.1212/01.wnl.0000073620.42047.d7 · Cited by 706
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
Alzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680 · cited 1×
“Vascular pathology of the aging brain and AD includes cerebral amyloid angiopathy (CAA), causing lobar mass hemorrhages, small or recurrent bleeds and ischemic infarcts, microvascular degeneration, disorder of the blood-brain barrier (BBB), WMLs, microinfarctions, lacunes, and cerebral hemorrhages [183].”
Hypertension Is Related to Cognitive Impairment: A 20-Year Follow-up of 999 Men
Kilander, L., Nyman, H., Boberg, M., Hansson, L., & Lithell, H. (1998) · Hypertension · doi:10.1161/01.hyp.31.3.780 · Cited by 630
Relation of diabetes to mild cognitive impairment
Luchsinger, J. A., Reitz, C., Patel, B., Tang, M.-X., Manly, J. J., & Mayeux, R. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.570 · Cited by 592
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Hypertension and Cerebrovascular Dysfunction
Iadecola, C., & Davisson, R. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.03.010 · Cited by 557
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547 · cited 7×
“Risk-enhancing mechanisms include the effects of insulin resistance, hyperglycemia-related increased advanced glycation end products (AGEs), and oxidative stress, inflammation, and macrovascular and microvascular injury [184] (Fig.”
InfluentialGlucocorticoids, stress, and their adverse neurological effects: relevance to aging
Sapolsky, R. M. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(99)00047-9 · Cited by 507
Lopez, O. L., Jagust, W. J., Dulberg, C., Becker, J. T., DeKosky, S. T., Fitzpatrick, A., Breitner, J., Lyketsos, C., Jones, B., Kawas, C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1394 · Cited by 477
Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., Nelson, J., Davis, D. G., Hardman, J., Foley, D. J., et al. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00106-8 · Cited by 468 · cited 1×
“Furthermore, there is a positive correlation between hypertension and vascular permeability accompanied with protein extravasation, as well as with the number of senile plaques and NFTs, a common finding in the AD brain [192].”
Kalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417 · cited 3×
“However, this suggested association between MetS and AD was not confirmed by four large longitudinal and population-based studies, the HAAS, the ThreeCity Study, the ILSA, and the cohort of Medicare recipients residing in northern Manhattan, in which no association between MetS and AD was found [156, 170,171,174] (Tab…”
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397 · cited 3×
“On the contrary, some follow-up studies, performed in larger populations, showed no association between HDL cholesterol levels and incident dementia, AD or VaD [149,154,155].”
Obesity and Hypertriglyceridemia Produce Cognitive Impairment
Farr, S. A., Yamada, K. A., Butterfield, D. A., Abdul, H. M., Xu, L., Miller, N. E., Banks, W. A., & Morley, J. E. (2008) · Endocrinology · doi:10.1210/en.2007-1722 · Cited by 382
Hypertension and the Risk of Mild Cognitive Impairment
Reitz, C., Tang, M.-X., Manly, J., Mayeux, R., & Luchsinger, J. A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.12.1734 · Cited by 360
The NIH Cognitive and Emotional Health Project: Report of the Critical Evaluation Study Committee
Hendrie, H. C., Albert, M. S., Butters, M. A., Gao, S., Knopman, D. S., Launer, L. J., Yaffe, K., Cuthbert, B. N., Edwards, E., & Wagster, M. V. (2006) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.11.004 · Cited by 323
MacKnight, C., Rockwood, K., Awalt, E., & McDowell, I. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000064928 · Cited by 313
Obesity‐related leptin regulates Alzheimer's Aβ
Fewlass, D. C., Noboa, K., Pi‐Sunyer, F. X., Johnston, J. M., Yan, S. D., & Tezapsidis, N. (2004) · The FASEB Journal · doi:10.1096/fj.04-2572com · Cited by 308 · cited 1×
“Furthermore, leptin has been associated with production and accumulation of Aβ [215] (Fig.”
Fontbonne, A., Berr, C., Ducimetière, P., & Alpérovitch, A. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.366 · Cited by 297
Kanaya, A. M., Barrett-Connor, E., Gildengorin, G., & Yaffe, K. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1327 · Cited by 255
Adiposity indices and dementia
Gustafson, D. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70526-9 · Cited by 237
The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women
Yaffe, K., Weston, A. L., Blackwell, T., & Krueger, K. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.566 · Cited by 220
Body mass index and incidence of dementia: The PAQUID study
Nourhashémi, F., Deschamps, V., Larrieu, S., Letenneur, L., Dartigues, J.-F., & Barberger-Gateau, P. (2003) · Neurology · doi:10.1212/01.wnl.0000038910.46217.aa · Cited by 193
Cardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature
Purnell, C., Gao, S., Callahan, C. M., & Hendrie, H. C. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318187541c · Cited by 189 · cited 4×
“As seen above, several individual components of MetS have been linked to risk of developing dementia and MCI [17,20–25].”
InfluentialMetabolic syndrome and dementia risk in a multiethnic elderly cohort
Muller, M., Tang, M.-X., Schupf, N., Manly, J. J., Mayeux, R., & Luchsinger, J. A. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105927 · Cited by 175 · cited 3×
“However, this suggested association between MetS and AD was not confirmed by four large longitudinal and population-based studies, the HAAS, the ThreeCity Study, the ILSA, and the cohort of Medicare recipients residing in northern Manhattan, in which no association between MetS and AD was found [156, 170,171,174] (Tab…”
Inflammation, Hypertension, and the Metabolic Syndrome
Grundy, S. M. (2003) · JAMA · doi:10.1001/jama.290.22.3000 · Cited by 170
The risk of dementia with increased body mass index
Gorospe, E. C., & Dave, J. K. (2006) · Age and Ageing · doi:10.1093/ageing/afl123 · Cited by 162 · cited 2×
“Epidemiological studies of increased BMI as a risk factor for dementia have shown conflicting results [102,128,129] (Table 3).”
Birns, J., Morris, R., Donaldson, N., & Kalra, L. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000244934.81180.16 · Cited by 96
Vanhanen, M., Koivisto, K., Karjalainen, L., Helkala, E.-L., Laakso, M., Soininen, H., & Riekkinen, P. (1997) · NeuroReport · doi:10.1097/00001756-199704140-00041 · Cited by 77
Cited by
Obesity and cognitive decline: role of inflammation and vascular changes
Nguyen, J. C. D., Killcross, A. S., & Jenkins, T. A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00375 · Cited by 425
Neurocognitive Impairment in Obstructive Sleep Apnea
Lal, C., Strange, C., & Bachman, D. (2012) · Chest · doi:10.1378/chest.11-2214 · Cited by 406
Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Self-citationFood for thought: how nutrition impacts cognition and emotion
Spencer, S. J., Korosi, A., Layé, S., Shukitt-Hale, B., & Barrientos, R. M. (2017) · npj Science of Food · doi:10.1038/s41538-017-0008-y · Cited by 268
Physiological changes in neurodegeneration—mechanistic insights and clinical utility
Ahmed, R. M., Ke, Y. D., Vucic, S., Ittner, L. M., Seeley, W., Hodges, J. R., Piguet, O., Halliday, G., & Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.23 · Cited by 91
Metadata
- Authors
- Panza, F., Frisardi, V., Capurso, C., Imbimbo, B. P., Vendemiale, G., Santamato, A., D'Onofrio, G., Seripa, D., Sancarlo, D., Pilotto, A., & Solfrizzi, V.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-09-02
- Volume
- 21
- Issue
- 3
- Pages
- 691-724
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1912107779
- Cited by
- 163
- References
- 58
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.